Marine Ingredients Denmark has submitted its consultation response to the Commission’s European Biotech Act proposal to Danish authorities.
Marine Ingredients Denmark (MID) has submitted a consultation response to the Danish Veterinary and Food Administration concerning the European Commission’s proposal for European Biotech Act I. The response was submitted on 8 April 2026.
MID welcomes that the European Biotech Act aims to strengthen innovation, streamline approval procedures and shorten processing times across sectors, including the food and feed industries.
Potential Indirect Impact on the Marine Ingredients Sector
MID notes that the proposal is primarily focused on health biotechnology. However, it also includes significant amendments to the General Food Law (Regulation (EC) No 178/2002) and to procedures under the European Food Safety Authority (EFSA), as set out in Chapter IX of the Commission’s proposal. These changes may have indirect effects on the marine ingredients sector.
The organisation emphasises that implementation of the legislation must ensure proportionality and predictability and should not result in increased costs for food and feed producers that use marine raw materials in their production.
EFSA Requirements and Compliance Costs
MID points out that changes to EFSA requirements, including documentation obligations, may entail additional costs related to external advisory services, updates to documentation procedures and staff competence development. Potential costs linked to new digital data requirements and IT systems are also highlighted.
More detailed data and documentation requirements could lead to higher ongoing compliance costs, including indirect costs passed on through suppliers and partners. At the same time, MID notes positively that the proposal may contribute to faster risk assessments and approval procedures, which could support innovation and shorten the time from development to market introduction.
Overall Assessment
Overall, Marine Ingredients Denmark assesses that the European Biotech Act may have a positive impact on innovation and efficiency in the food and feed value chain, provided that amendments to the General Food Law and EFSA procedures are implemented proportionately and with due consideration for sectors not directly engaged in health biotechnology, in order to avoid unnecessary administrative burdens.
